Nearly half of FDA-approved prescription drug products are no longer marketed

Of the 4,994 FDA-approved prescription drug products in our catalog, 2,404 (48%) are no longer actively marketed.

What this does — and does not — mean

These figures count drug products— specific brand-and-formulation records in the FDA’s Drugs@FDA database — not active ingredients. A high discontinuation rate mostly reflects how the generic market churns: when one manufacturer retires an older version, an equivalent from another maker usually remains on the market. So a discontinued product rarely means the medicine itself is unavailable. It is a measure of product turnover, not of patients losing access to treatment. (OTC medicines and supplements are excluded — the FDA does not track a marketing status for them.)

4,994

Rx products analyzed

48%

no longer marketed

2,590

still marketed

Drug classes with the highest product churn

Share of each class’s prescription products that are discontinued (classes with at least 25 products). Cephalosporin Antibacterial leads — 76% of its 42 products are retired, typically as newer agents in the class replaced older ones.

cephalosporin antibacterial76%

azole antifungal71%

histamine-1 receptor antagonist63%

corticosteroid61%

nonsteroidal anti-inflammatory drug61%

antiarrhythmic55%

opioid agonist54%

The most enduring drug classes

By contrast, these classes keep the largest share of their products on the market — a sign of stable, still-prescribed product lines.

kinase inhibitor6%

central nervous system stimulant10%

radiographic contrast agent23%

atypical antipsychotic26%

anti-epileptic agent26%

alkylating drug29%

Method & source

Computed live from the marketing-status field of the U.S. FDA’s Drugs@FDA database, across every prescription drug product in our catalog. “Discontinued” is the FDA’s own status. Nothing is estimated. Figures update as our data refreshes. This is information, not medical advice — if a medicine you take has been discontinued, ask your pharmacist about an equivalent.